Wildlife Epidemiology Laboratory, University of Illinois Urbana-Champaign, Urbana, IL 61802, USA,
Franz Theodore Stone Laboratory, The Ohio State University, OH 43456, USA.
J Zoo Wildl Med. 2024 Jan;54(4):746-756. doi: 10.1638/2023-0050.
Ophidiomycosis (snake fungal disease) is an important infectious disease caused by the fungus . To mitigate the disease's impact on individual snakes, a controlled clinical trial was conducted using terbinafine nebulization to treat snakes with ophidiomycosis. Fifty-three wild-caught Lake Erie watersnakes () with apparent ophidiomycosis (skin lesions present, qPCR positive for ) were divided into treatment and control groups: treatment snakes were nebulized with a 2 mg/ml terbinafine solution for 30 min daily for 30 d; control snakes received nebulization with 0.9% saline or no nebulization. Weekly physical exams were conducted to assign disease severity scores based on the number, type, location, and size of lesions, and qPCR was repeated after each 30-d course of treatment. Persistently qPCR-positive snakes received multiple nebulization courses. Terbinafine nebulization showed mixed results as a treatment for ophidiomycosis: 29.2% of animals treated with terbinafine showed molecular resolution of external disease, based on antemortem swabbing, following 3-6 mon of daily nebulization; this was significantly more than with saline nebulization (5%), but molecular resolution also occurred in 11.1% of snakes that received no treatment. Terbinafine nebulization did not significantly decrease clinical disease, as measured by disease severity scores. Evaluating molecular response to treatment using fungal quantities, terbinafine nebulization significantly reduced fungal quantity after three or more courses of treatment. These results indicate that, although terbinafine nebulization is a promising treatment for ophidiomycosis, snakes may require multiple nebulization courses and disease may not always resolve completely, despite treatment. This treatment may be most useful in snakes from managed populations that can be treated for several months, rather than wild snakes who are not releasable after multiple months in captivity.
蛇真菌病(ophidiomycosis)是一种由真菌引起的重要传染病。为了减轻该病对蛇类个体的影响,我们进行了一项针对患有蛇真菌病的蛇类使用特比萘芬雾化治疗的对照临床试验。将 53 条野生捕获的伊利湖水蛇()分为治疗组和对照组:治疗组蛇每日雾化 2mg/ml 的特比萘芬溶液 30 分钟,共 30 天;对照组蛇雾化 0.9%生理盐水或不进行雾化。每周进行体格检查,根据病变的数量、类型、位置和大小给疾病严重程度评分,并在每个 30 天疗程后重复 qPCR。持续 qPCR 阳性的蛇接受多次雾化治疗。特比萘芬雾化治疗蛇真菌病的效果喜忧参半:3-6 个月每日雾化治疗后,29.2%的特比萘芬治疗动物的外部疾病经生前拭子检查显示分子学缓解;这显著高于盐水雾化组(5%),但也有 11.1%未接受治疗的蛇出现分子学缓解。从疾病严重程度评分来看,特比萘芬雾化治疗并未显著降低临床疾病。通过真菌数量评估治疗的分子反应,特比萘芬雾化治疗在三个或更多疗程后显著降低了真菌数量。这些结果表明,尽管特比萘芬雾化治疗是蛇真菌病的一种有前途的治疗方法,但蛇可能需要多次雾化治疗,而且尽管进行了治疗,疾病也不一定能完全缓解。这种治疗方法可能对可以治疗数月的管理种群中的蛇最有用,而对无法在圈养中存活数月的野生蛇则不适用。